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CTC countBackground: CTCs provide prognostic information and their application is under investigation in multiple tumor
types. Of themultiple variables inherent in any such process, none ismore important to outcome than the appro-
priateness of the sample source. To address this question, we investigated CTCs in paired peripheral venous and
arterial blood specimens obtained from stage IV uveal melanoma patients.
Methods: Blood specimens were obtained from both common femoral arteries and antecubital veins in 17 uveal
melanoma patients with multiple hepatic metastases for CTC measurements.
Finding:CTCswere detectablewith greater frequency (100%) and in larger numbers (median 5, range 1 to 168) in
all arterial blood specimens than in venous samples (52.9%;median 1, range 0 to 8). Patients with hepatic aswell
as extra-hepatic metastasis showed higher number of arterial CTCs, compared to patients with liver-onlymetas-
tasis (p = 0.003). There was no signiﬁcant association between the number of arterial CTCs and the tumor bur-
den within the liver in patients who had liver-only metastases.
Interpretation: Our data indicate that arterial blood specimens might be a better source of circulating uveal mel-
anoma cells. Although less conveniently processed, perhaps arterial blood should be evaluated as sample source
for measurement of CTCs.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Uveal melanoma (UM) is the most common primary cancer of the
eye in adults, with a reported incidence of 5.1 per million (Singh et al.,
2011). Themajority of UM cases (97.8%) occur in the Caucasian popula-
tion (Singh et al., 2011). Despite the common embryologic origin of cu-
taneous and uveal melanocytes, the clinical, epidemiologic, and
molecular characteristics of UM differ from those of cutaneous melano-
ma (Collaborative Ocular Melanoma Study G, 2001; Singh et al., 2001;
Ewens et al., 2014). Local treatment of primary UM has improved; con-
servative non-surgical treatments such as brachytherapy with radioiso-
topes result in eye preservation and control the growth of primary UM.NU, bischlorethylnitrosourea;
hylenediaminetetraacetic acid;
d antigen; Ipi, ipilimumab; LN,
hibitor;; TACE, transarterial
erapy.
cology, Sidney Kimmel Medical
et, Suite 1024, Philadelphia, PA
. This is an open access article underHowever, this improvement in local treatment did not signiﬁcantly in-
crease the overall survival for UM patients (Singh et al., 2011). Systemic
metastases develop in up to 50% of the cases of UM patients. UM dis-
seminates hematogeneously, as there is no major lymphatic drainage
from the eye. Metastatic disease leads to death in the majority of pa-
tients because of the lack of effective systemic treatments (Kujala
et al., 2003). The metastatic UM cells have signiﬁcant tropism to the
liver, and the liver is the ﬁrst organ of metastasis in approximately
80% to 95% of patients who develop systemic recurrence. Several histo-
logic, genetic, and demographic factors have been associated with me-
tastases in UM, including large tumor size in primary cancer of the
eye, monosomy 3, and BAP1 mutation (Collaborative Ocular
Melanoma Study G, 2001; Ewens et al., 2014). It has been reported
that 80% of metastatic uveal melanoma have mutation in BAP1
(Harbour et al., 2010). Published clinical observations suggested that
UM cell metastases in the liver grow faster than metastases in other or-
gans (All-Ericsson et al., 2002; Yoshida et al., 2014; Chattopadhyay et al.,
2014). The lung is the second most common site of metastasis. A small
percentage of patients ﬁrst develop osseous and brain metastasis
(Lorigan et al., 1991; Rietschel et al., 2005). It has been reported that dis-
tant micrometastasis resulting from the dissemination of tumor cellsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ically diagnosed and treated (Eskelin et al., 2000). It is also reported that
the recurrence for patients undergoing enucleation displays a bimodal
pattern, peaking three years with a second surge peaking at about
nine years (Demicheli et al., 2014).
Due to their buoyancy, circulating tumor cells (CTCs) are found in
the white blood cell fraction. CTCs have been investigated as a non-
radiographic tool to monitor disease progression. The presence of
CTCs suggests increasedmetastatic potential, and they have been inves-
tigated as a predictive marker for systemic recurrence. They could also
serve as a source for diagnostic testing (liquid biopsy) in cases where
the biopsy of metastases is difﬁcult or risky. In such cases, evaluation
of CTCs in blood would be more convenient and could be useful in
obtaining critical information on the biological characteristics of
cancer cells to facilitate a diagnostic or therapeutic decision. Further-
more, the genomic proﬁle of CTCs may predict homing and coloniza-
tion to speciﬁc distant organ sites (Li et al., 2008; Burger and Kipps,
2006).
CTCs have been detected in themajority of epithelial cancers, includ-
ing those from the prostate (Danila et al., 2007), colon/rectum (Cohen
et al., 2008), and breast (Cristofanilli et al., 2004). In patients with met-
astatic breast cancer, CTC counts above 5 per 7.5ml of venous blood be-
fore the start of systemic therapy are associated with shorter median
progression-free and overall survivals (Cristofanilli et al., 2008). The
key mutation for therapeutic resistance has been found in CTCs in met-
astatic breast cancer patients and CTCs could potentially be used as a
predictable marker for treatment response and resistance (Fernandez
et al., 2014). In fact, the CellSearch® System was approved by the
United States (US) Food and Drug Administration (FDA) for monitoring
treatment effectiveness in metastatic prostate, colorectal, and breast
cancer patients.
Venous blood collection is simple and minimally invasive, and this
approach has made CTC testing readily available to many cancer
patients. Themajor drawback is the fact that CTCs are not always detect-
able for patientswith clinically evidentmetastatic disease. This observa-
tion raises the concern that a number of CTCs might have been
sequestered or destroyedwhile circulating in the blood stream. Alterna-
tively, it is possible that CTCs may have been lost during analysis due to
technical reasons.
Recently, the ﬁeld of CTC detection technologies has been signiﬁ-
cantly improved and various new approaches have been developed
including ﬁltration (Mazzini et al., 2014), dual immunomagnetic en-
richment assay (Tura et al., 2014), ﬁber-optic array scanning (Krivacic
et al., 2004), microﬂuidics (Dong et al., 2013) and photoacoustic-ﬂow
cytometry (Menyaev et al., 2013; Sarimollaoglu et al., 2014). However,
none of these new technologies have been validated for approval by the
US FDA.
Although accumulative evidence suggests that CTCs could provide
prognostic information in breast cancer patients, the clinical beneﬁts in
measuring CTCs in UM patients remain controversial. It has been shown
that the detection of CTCs in venous blood specimens of primary UM pa-
tients prior to their local treatment was 14% with an immunomagnetic
enrichment method. However, there was no signiﬁcant difference be-
tween the number of CTCs before and after their local therapies, and
the number of CTCs was not correlated to the development of metastasis
in a short median follow-up time of 16 months (Suesskind et al., 2011).
Bidard et al. reported the result of CTC detection with the CellSearch®
method in 40 stage IV UM patients with liver metastasis, in which eight
out of 40 patients exhibited additional extra-hepatic metastasis. Surpris-
ingly, no CTCs were detected in 70% of patients with hepatic metastasis.
The median number of CTCs was 3 and the range of CTCs was 1 to 20 in
12 patients who showed positive CTCs in their venous blood specimens
(Bidard et al., 2014). These results indicate that CTC measurement in ve-
nous bloodmay not be useful in stage IV UM patients since the detection
rate of CTCs is very low. This also raises the critical question as towhether
venous blood specimens are appropriate in evaluating CTCs in UMpatients. UM CTCs might have been sequestered or destroyed in periph-
eral tissues or, alternatively, CTCs might have strong organ tropism and
therefore they are repeatedly cleared from peripheral blood. The number
of CTCsmay also differ in different blood sources. To address these issues,
we investigated the number of CTCs in paired blood specimens fromboth
common femoral arteries and antecubital veins of the same patientswith
stage IV UM.
2. Patients and Methods
The protocol for blood specimen procurement was approved by the
Institutional Review Board of Thomas Jefferson University. Seventeen
UM patients, including ten patients who had liver only metastasis and
seven patients who had hepatic and extra-hepatic metastases, were en-
rolled in this study between April 2014 and October 2014. All patients
had treated their primary uveal melanoma between 2000 and 2013.
Ten patients had received radioactive plaque as their treatment for
primary uveal melanoma and seven patients had enucleation of their
affected eye. None of these patients had a local recurrence of primary
uveal melanoma at the time of CTC measurement. The patients signed
the informed consent form prior to blood sample collection. All patients
were scheduled to receive liver-directed therapy for metastatic UM.
Prior to liver embolization treatment, 7.5 ml of blood samples was
obtained from the common femoral arterial and the antecubital
(forearm) veins, using CellSave tubes (Veridex, LLC, Raritan, NJ), and
sent to the CTC measurement laboratory. The clinical information and
the sources of blood were blinded to the CTC laboratory. Blood samples
were maintained at room temperature and processed within 72 h of
collection.
CTCs were analyzed using the standard CellSearch® protocol and
CellTracks Circulating Melanoma Cell Kit® on the CellSearch® System
(Janssen Diagnostics, LLC, Raritan, NJ). Brieﬂy, cells expressing CD146
(Mel-CAM) were immunomagnetically enriched and stained with phy-
coerythrin (PE)-conjugated antibody speciﬁc to high molecular weight
melanoma associated antigen (HMW-MAA), which is speciﬁc for mela-
noma cells. Allophycocyanin (APC)-conjugated anti-CD45 was used to
identify leukocytes and anti-CD34 was used for detection of endothelial
cells. 4,6-Diamidino-2-phenylindoledihydrochloride (DAPI) was used
to detect cell nuclei. CTCs were deﬁned as nucleated, CD146-positive
cells, expressing HMW-MAA, but lacking expression of the common
leukocyte antigen CD45 and CD34 endothelial markers. Samples were
then scanned on the CellTracks® analyzer II ﬂuorescent microscope
(Veridex, LLC, Raritan, NJ) (Fig. 1). This technology is widespread and
widely used in different counties, notably in the USA. The validity of
this assay was conﬁrmed by the Control Kit for Circulating Endothelial
and Melanoma Cells provided by the manufacturer (Janssen Diagnos-
tics, LLC). The control kit contains ﬁxed cells from a SK-Mel-28 cell
line in the bottles containing two populations of cell for high and low
control. The control cells are fully compatible with CellSearch Endothe-
lial Cell and CellTracks Circulating Melanoma Cell Kit reagents and are
automatically identiﬁed by the CellTracks analyzer. The detected ﬁxed
SK-Mel-28 cells in two different lots for the studied melanoma CTC
measurements were as follows: Lot #1: 1272 (mean) with the range
of 1058–1486 in high control, and 62 (mean) with the range of 32 to
92 in low control; and Lot #2: mean of 1203 and the range of 719–
1687 in high control, and mean of 53 and the range 11 to 95 in low
control.
We also conducted exploratory experiments by adding UM cells to
the healthy donor peripheral blood. In the ﬁrst spiking experiment, var-
ious numbers of melanoma cell (5, 15, 30, 100, 500, and 1500 cells) ob-
tained from a long-term cultured metastatic UM cell line (TJU-UM001)
were added to 6 tubes ofwhole blood specimen obtained froma healthy
donor. Various numbers of ﬁxed melanoma cells were diluted in
CellSearch Dilution Buffer® and then added to 7.5 ml of whole blood.
The information regarding numbers of melanoma cell in individual
specimens was blinded to examiners and spiked UM cells were
Fig. 1.Gallery of circulating tumor cells (CTCs) from the CellSearch Analyzer. Representative cell images obtained from patients using themelanoma detection kit. Figure shows represen-
tative images of CTCs from three patients on the CellTracks analyzer II. To be assigned as CTC, cells must have PE-stained nucleus (pseudocolored pink) and positive HMW-MAA staining
(pseudocolored green).
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in all specimens spiked with at least 5 tumor cells in 7.5 ml blood
(100% detection rate) (Supplement 1). Furthermore, in a separate
experiment, we have prepared 3 tubes of the same healthy donor
blood specimen. Each tube was ﬁrst irradiated (25Gy) and then
20 UM cells were added. Melanoma cells were measured by the same
method as described above. We have detected 4 tumor cells in each of
these 3 tubes.
For patients with liver metastases only, the number of circulating
CTCs in arterial blood specimenswas compared to tumor burdenwithin
the liver. Using MRI of the abdomen patients were categorized into
three groups: 1) less than 20% of liver involvement, 2) between 20%
and 50% of liver involvement, and 3) more than 50% of liver involve-
ment. The maximum diameter of tumor in liver metastasis was mea-
sured with MRI images.
2.1. Statistical Analysis
The CTC numbers per patient in subgroups of patients were summa-
rized as medians and inter-quartile and full ranges. The difference be-
tween numbers of CTC in arterial and venous blood specimens was
tested using the nonparametricWilcoxon signed rank test for the paired
data. The null hypothesis tested is that within-patient differences be-
tween CTC numbers in arterial and venous blood have a symmetric dis-
tribution around zero (the median difference is zero). The Spearman
correlation coefﬁcient was used to evaluate association between the
size of the largest hepatic metastasis and the numbers of CTC. The non-
parametric Kruskal–Wallis rank sum test was used to evaluate associa-
tion between the numbers of CTC in arterial blood specimens of 10
patients who have liver-only metastases. The null hypothesis tested is
that numbers of CTC in arterial blood specimens have the same distribu-
tion in patients who have hepatic and extra-hepatic metastases and in
patients who have liver-only metastasis. The nonparametric Kruskal–
Wallis rank sum test was used to compare numbers of CTC in arterial
blood specimens of patients with three different levels of liver-only
tumor involvement (b20%, 20%–50%, N50%). The null hypothesis tested
is that the numbers of CTC have the same distribution in arterial blood
specimens from patients with liver-only metastases but different level
of tumor involvement. The data were analyzed in R (The R Foundation
for Statistical Computing, http://www.R-project.org).
3. Results
Demographic information of patients and their treatment histories
are shown in Table 1. The 17 UM patients with multiple hepaticmetastases comprised seven males and ten females, of mean age 59.4
(range 35 to 79) years. Ten patients had liver-only metastasis by radio-
graphic evaluation, and 7 patients had hepatic and extra-hepaticmetas-
tases. In 7 patients who have extra-hepatic metastatic, all patients have
bone metastases and 3 patients have lung metastases (Table 1). Fifteen
out of 17 patients had previous treatments including liver-directed
treatments (n = 13) and systemic treatments (n = 9) before being
enrolled into this study. Despite these treatments, their hepatic metas-
tases were radiographically and clinically active and all patients subse-
quently received a liver-directed treatment after collection of blood
specimens.
In the representative images, no obvious morphological difference
of CTCs between arterial and venous blood was observed. CTCs clusters
were not seen either (Fig. 1). CTCs were detected in all common femoral
arterial blood specimens (100%) from these UM patients with multiple
hepatic metastases (Fig. 2). The median number of CTCs in arterial
blood was 5 (minimum 1, maximum 168), and inter-quartile range
was from 4 to 11 CTCs. In contrast, CTCs were detectable in only
9/17 (52.9%) of peripheral venous blood specimens from the same
patients. The median number of CTCs in the venous blood samples
was 1 (minimum 0, maximum 8), and inter-quartile range from 0 to
2 CTCs with statistically signiﬁcant difference between arterial blood
specimens and peripheral venous blood specimens (p b 0.001).
It is of note that there is no signiﬁcant association between numbers
of arterial or venous CTC and extent of tumor burdenwithin the liver or
the size of the largest tumor. The arterial CTC numbers of 10 patients
who had liver-only metastases were not proportional to the volume of
liver involvement by metastasis (p = 0.423) (Fig. 3). Furthermore,
there was no signiﬁcant correlation between the size of the largest he-
patic metastasis and numbers of CTC in arterial blood of patients who
have liver-only metastases (coefﬁcient 0.074, p = 0.839).
In terms of sites ofmetastasis, 7 patients who have hepatic aswell as
extra-hepaticmetastases showed signiﬁcantly higher numbers of CTC in
arterial blood specimens (median 12, minimum 5, maximum 168, and
inter-quartile range from 10 to 43.5), compared to the arterial
numbers of CTC in 10 patients who have liver-only metastasis (median
4, minimum 1, maximum 11, and inter-quartile range from 2.5 to
5) (p = 0.003) (Fig. 4). There was no signiﬁcant correlation between
the presence of extra-hepatic metastasis and the total liver involvement
by metastasis or the size of the largest hepatic metastasis.
4. Discussion
In this small pilot study, we detected CTCs in all arterial blood sam-
ples from UM patients who have multiple hepatic metastases. In
Table 1
Demographic characteristic and treatment histories of 17 patients with stage IV uveal melanoma.
ID Gender Age Tumor volume
in liver (%)
Largest tumor
in liver (cm)
Extra-hepatic metastasis Previous treatment liver-directed Previous treatment others
1 F 58 20–50 1.7 None Immunoembolization, radiosphere, TACE with BCNU Ipi
2 M 79 b20 2.2 None None None
3 F 77 b20 2.3 Bone Radiosphere, immunoembolization, TACE with BCNU None
4 M 68 20–50 3.2 Bone, periportal LN, lung Immunoembolization, TACE with BCNU Carbo + Taxol, Xgeva, Ipi
5 F 68 b20 3.4 Lung, bone Immunoembolization MET Ab + MEKi, Ipi
6 M 46 b20 3.5 None Immunoembolization Adjuvant Sutent
7 M 64 b20 3.9 None None Adjuvant Sutent, METi
8 F 35 b20 4.4 Breast, pancreas,
mediastinal LN, bone
Immunoembolization Gemcitabine + Abraxane, VPA,
MEKi, Cryoablation of pelvic metastasis
9 F 78 b20 4.5 Spine, skin Immunoembolization, XRT to liver tumor,
TACE with BCNU
None
10 F 66 b20 4.6 None None MEKi + AKTi, Ipi
11 F 53 b20 4.7 Bone, peritoneum, lung Immunoembolization, TACE with BCNU MET Ab, Ipi, VPA,
PD-1 Ab
12 M 63 20–50 6.9 None TACE with BCNU, DEBDOX None
13 F 50 20–50 7.4 None TACE with BCNU, DEBDOX None
14 M 36 20–50 8.2 None None None
15 F 40 N50 10.4 None TACE with BCNU, DEBDOX Ipi
16 F 58 N50 13.1 None TACE with BCNU None
17 M 71 20–50 14.3 Muscle, brain, bone,
peritoneum, skin
TACE with BCNU, DEBDOX XRT to brain
Note: Patients were sorted according to the size of the largest hepatic metastasis. Immunoembolization, embolization with granulocyte macrophage colony-stimulating factor plus
Interleukin-2.
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in peripheral venous blood. Only half of venous blood specimens were
positive for CTCs in stage IV UMpatients. Since tumor cells may become
apoptotic and fragmented while circulating in the peripheral venous
system (Mehes et al., 2001), CTCs in the peripheral vein might not be
the same as those in arterial blood and could be more fragile. In fact,
our data have shown that numbers of CTC remarkably dropped in the
peripheral venous circulation, compared to those in arterial blood, im-
plying that venous blood specimensmight not be an appropriate source
for detection of CTCs in UM patients.
Due to the technical convenience and the assumption that CTCs ob-
tained from the peripheral venous circulation represent the characteris-
tics of metastasis, “venous blood specimens” have been used for
detection of CTCs in cancer patients. This is based on the assumption
that the sensitivity of the CTC detection methods is sufﬁcient enough
to detect CTCs in venous blood. Unfortunately, this assumption has
not been proven to be true in various types of cancers including meta-
static UM. As reported by Bidard's group, CTC detection with the
CellSearch®methodwas only successful in 30% of UMpatients with he-
patic metastasis although numbers of CTC were associated with the
presence of miliary hepatic metastasis (p b 0.004), metastasis volume
(p= 0.005), progression-free survival (p= 0.003), and overall survival
(p = 0.0009) (Bidard et al., 2014). Despite the correlation between ve-
nous CTCs and clinical outcome in a limitednumber of patients, it clearlyFig. 2. Numbers of CTC in peripheral arterial and venous blood specimens. Each column
shows CTC numbers in arterial (red column) or venous (blue column) blood specimen
in the same patient.shows that detection of venous CTCs is not sensitive enough to be used
as a predictive marker for the presence of systemic metastasis. Similar
results have been obtained from the investigation on stage IV breast
cancer patients (Weissenstein et al., 2012). In 59 patients withmetasta-
tic breast cancer, CTCs were not detectable in 20 patients using
cytokeratin and EpCAM antibodies. These results indicate that currently
available technology using venous blood specimens is not suitable for
early detection of metastatic disease. This also limits the clinical utiliza-
tion of venous CTCs in stage IV cancer patients since radiographic imag-
ing is much more sensitive in detecting and evaluating metastatic
disease. A limited number of patients might have beneﬁt by measuring
CTCs after their treatments since better correlation has been seen be-
tween changes in numbers of CTC and their survival, compared to that
of radiographic images (Budd et al., 2006); however, this observation
would not be sufﬁcient enough to change our standard practice in
using radiographic images to evaluate the response to treatments in
metastatic breast cancer patients. This would also raise the concern in
using venous blood CTC as a surrogatemarker to predict poor prognosis
in patients with metastatic UM. In this regard, investigation of arterial
blood specimens, rather than peripheral venous specimens, would be
more sensitive in detection of CTCs in stage IV UM patients. Despite
technical challenges, changing the source of blood specimens from pe-
ripheral vein to peripheral artery might open a new window ofFig. 3. Hepatic tumor volume and numbers of arterial CTC in patients with liver-only me-
tastases. Each column showed the CTC numbers in individual patients. Blue columns: liver
involvement with tumor b20%; purple columns: 20–50%; and green columns: N50%.
Fig. 4.Numbers of arterial CTC inuvealmelanomapatientswith andwithout extra-hepatic
metastases. Numbers of CTC detected in patients who had hepatic and extra-hepatic me-
tastases liver-onlymetastaseswere higher than those obtained frompatientswith hepatic
metastases only (p = 0.003).
1825M. Terai et al. / EBioMedicine 2 (2015) 1821–1826opportunity in utilizing CTCs as a surrogate prognostic marker for stage
IV cancer patients, including UM.
It has been reported that a CTC-like cell could be detectable in the ve-
nous blood of healthy volunteers. By using the CellSearchmelanoma kit,
one CTC like cell was detected in the peripheral blood of 3 out of 55
healthy donors (Rao et al., 2011). This phenomenon could be explained
by contamination of skinmelanocytes during venipuncture and itmight
not necessarily be “false positive”. It is less likely that this is related to
real “false positive” detection since the CellSearch System is a well
established and validated technique with FDA approval for detection
of various cancer cells. False positive results due to the contaminated
skin melanocytes are not our concern for this study since arterial
blood specimens were collected after ﬂushing the catheter and
discarding the ﬁrst 5 ml of blood return before collecting blood speci-
mens for CTC measurements.
It must also be emphasized that numbers of CTC did not correlate to
the volume of hepatic metastasis in our patient population. It is also of
note that CTC numbers tend to be higher in patients who had hepatic
and extra-hepatic metastases. Our data indicate that the number of
CTCs in the arterial blood is not reﬂective of the tumor volume in the
liver, but instead, it may reﬂect different biological features of tumor
cells such as less cohesiveness (scattering) and metastatic ability to
other organs; therefore, they may have distinct prognostic contribution
that cannot be obtained by standard radiographic evaluation.
Kinetics of CTCs has been investigated in colon cancer and hepato-
cellular carcinoma. Jiao et al. measured CTCs in different blood compart-
ments before and after surgical intervention or radiofrequency ablation
of hepatic metastasis in 29 colon cancer patients. CTCs were examined
in both systemic and portal circulation by obtaining blood samples
from the peripheral vein and the artery, the portal vein, and the hepatic
vein. They reported that CTCs were much higher in the hepatic porto-
systemic circulation, compared to peripheral systemic circulation, indi-
cating that the majority of CTCs from hepatic metastases are trapped
during the lung circulation (Jiao et al., 2009). Fang et al. detected and
quantiﬁed CTCs in the peripheral veins and right atrium in patients
with hepatocellular carcinoma using Ep-CAM antibody-conjugated
magnetic beads. The detection rates of CTC were signiﬁcantly higher
in the right atrium, compared to peripheral venous blood (73.8% versus
52.4%). The number of CTCswere also higher in blood obtained from the
right atrium (median 6, interquartile range 15.5), compared to those inperipheral venous blood (median 1, interquartile range 5.5) (Fang et al.,
2014). These studies indicate that the lung circulation would be the
major determining factor for CTCs in peripheral circulation and the de-
velopment of systemic metastasis. In this regard, arterial CTCs passing
through the lung circulation might have more potential in the develop-
ment of systemic recurrence, which is consistent with our observation,
in which CTC numbers were higher in patients with hepatic and extra-
hepatic metastases. Future investigation on CTCs in pre- and post-lung
circulation would provide important insight into this speculation.
The natural history of UM is poorly understood. Due to the lack of a
lymphatic draining system, UM cells disseminate hematogeneously. In
this regard, the detection of circulating melanoma cells may potentially
be useful for the diagnosis, risk stratiﬁcation, monitoring of disease pro-
gression, and analysis of treatment efﬁcacy. Our data indicates that arte-
rial blood, rather than venous blood, might be suitable for future
investigation on CTCs in UM patients. This would also raise the concern
as to whether venous blood specimens are a suitable source for investi-
gation on CTCs in other types of cancer. Further investigation to address
this fundamental question should be warranted.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.09.019.
Contributors
MT assembled and interpreted data on CTCs and wrote this manu-
script. MJM, MC, and TS designed the study and interpreted data. DE,
CG, and TS enrolled patients for this study and collected specimens.
MT, ZM and KK analyzed CTCs. IC performed statistical analysis on the
data. MO and RW coordinated this study.
All authors reviewed and approved the ﬁnal draft of the paper.
Conﬂicts of interest
We declare that we have no conﬂicts of interest.
Acknowledgments
The authors thank TraceyNewhall, RN, Katherine Sohon, BS,Mitchell
Berkowitz, BS, and Shingo Sato, BS for the coordination of this study and
blood specimen collections. A part of the results in this study was pre-
sented at the American Association for Cancer Research (AACR) annual
meeting in Philadelphia, PA (2015).
This study was supported by the Wills Vision Research Center at
Jefferson Innovation Grant, Bonnie Kroll Research Fund, MarkWeinziel
Research Fund, and Eye Melanoma Research Fund at Thomas Jefferson
University.
References
All-Ericsson, C., Girnita, L., Seregard, S., Bartolazzi, A., Jager, M.J., Larsson, O., 2002. Insulin-
like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease
and a potential therapeutic target. Invest. Ophthalmol. Vis. Sci. 43 (1), 1–8.
Bidard, F.C., Madic, J., Mariani, P., Piperno-Neumann, S., Rampanou, A., Servois, V.,
Cassoux, N., Desjardins, L., Milder, M., Vaucher, I., et al., 2014. Detection rate and prog-
nostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal
melanoma. Int. J. Cancer 134 (5), 1207–1213.
Budd, G.T., Cristofanilli, M., Ellis, M.J., Stopeck, A., Borden, E., Miller, M.C., Matera, J.,
Repollet, M., Doyle, G.V., Terstappen, L.W., et al., 2006. Circulating tumor cells versus
imaging–predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12
(21), 6403–6409.
Burger, J.A., Kipps, T.J., 2006. CXCR4: a key receptor in the crosstalk between tumor cells
and their microenvironment. Blood 107 (5), 1761–1767.
Chattopadhyay, C., Grimm, E.A., Woodman, S.E., 2014. Simultaneous inhibition of the
HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.
PLoS One 9 (2), e83957.
Cohen, S.J., Punt, C.J., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y., Picus, J.,
Morse, M., Mitchell, E., Miller, M.C., et al., 2008. Relationship of circulating tumor
cells to tumor response, progression-free survival, and overall survival in patients
with metastatic colorectal cancer. J. Clin. Oncol. 26 (19), 3213–3221.
1826 M. Terai et al. / EBioMedicine 2 (2015) 1821–1826Collaborative Ocular Melanoma Study G, 2001. Assessment of metastatic disease status at
death in 435 patients with large choroidalmelanoma in the Collaborative Ocular Mel-
anoma Study (COMS): COMS report no. 15. Arch. Ophthalmol. 119 (5), 670–676.
Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C., Reuben, J.M.,
Doyle, G.V., Allard, W.J., Terstappen, L.W., et al., 2004. Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351 (8),
781–791.
Cristofanilli, M., Reuben, J., Uhr, J., 2008. Circulating tumor cells in breast cancer: ﬁction or
reality? J. Clin. Oncol. 26 (21), 3656–3657 (author reply 3657-3658).
Danila, D.C., Heller, G., Gignac, G.A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., Lilja, H.,
Schwartz, L., Larson, S., Fleisher, M., et al., 2007. Circulating tumor cell number and
prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13
(23), 7053–7058.
Demicheli, R., Fornili, M., Biganzoli, E., 2014. Bimodal mortality dynamics for uveal mela-
noma: a cue for metastasis development traits? BMC Cancer 14, 392.
Dong, Y., Skelley, A.M., Merdek, K.D., Sprott, K.M., Jiang, C., Pierceall, W.E., Lin, J., Stocum,
M., Carney, W.P., Smirnov, D.A., 2013. Microﬂuidics and circulating tumor cells. J. Mol.
Diagn. 15 (2), 149–157.
Eskelin, S., Pyrhonen, S., Summanen, P., Hahka-Kemppinen, M., Kivela, T., 2000. Tumor
doubling times in metastatic malignant melanoma of the uvea: tumor progression
before and after treatment. Ophthalmology 107 (8), 1443–1449.
Ewens, K.G., Kanetsky, P.A., Richards-Yutz, J., Purrazzella, J., Shields, C.L., Ganguly, T.,
Ganguly, A., 2014. Chromosome 3 status combined with BAP1 and EIF1AX mutation
proﬁles are associated with metastasis in uveal melanoma. Invest. Ophthalmol. Vis.
Sci. 55 (8), 5160–5167.
Fang, Z.T., Zhang, W., Wang, G.Z., Zhou, B., Yang, G.W., Qu, X.D., Liu, R., Qian, S., Zhu, L., Liu,
L.X., et al., 2014. Circulating tumor cells in the central and peripheral venous compart-
ment— assessing hematogenous dissemination after transarterial chemoembolization
of hepatocellular carcinoma. Onco Targets Ther. 7, 1311–1318.
Fernandez, S.V., Bingham, C., Fittipaldi, P., Austin, L., Palazzo, J., Palmer, G., Alpaugh, K.,
Cristofanilli, M., 2014. TP53 mutations detected in circulating tumor cells present in
the blood of metastatic triple Negative breast cancer patients. Breast Cancer Res. 16
(5), 445.
Harbour, J.W., Onken, M.D., Roberson, E.D., Duan, S., Cao, L., Worley, L.A., Council, M.L.,
Matatall, K.A., Helms, C., Bowcock, A.M., 2010. Frequent mutation of BAP1 inmetasta-
sizing uveal melanomas. Science 330 (6009), 1410–1413.
Jiao, L.R., Apostolopoulos, C., Jacob, J., Szydlo, R., Johnson, N., Tsim, N., Habib, N.A.,
Coombes, R.C., Stebbing, J., 2009. Unique localization of circulating tumor cells in pa-
tients with hepatic metastases. J. Clin. Oncol. 27 (36), 6160–6165.
Krivacic, R.T., Ladanyi, A., Curry, D.N., Hsieh, H.B., Kuhn, P., Bergsrud, D.E., Kepros, J.F.,
Barbera, T., Ho, M.Y., Chen, L.B., et al., 2004. A rare-cell detector for cancer. Proc.
Natl. Acad. Sci. U. S. A. 101 (29), 10501–10504.
Kujala, E., Makitie, T., Kivela, T., 2003. Very long-term prognosis of patients with malig-
nant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 44 (11), 4651–4659.Li, H., Alizadeh, H., Niederkorn, J.Y., 2008. Differential expression of chemokine receptors
on uveal melanoma cells and their metastases. Invest. Ophthalmol. Vis. Sci. 49 (2),
636–643.
Lorigan, J.G., Wallace, S., Mavligit, G.M., 1991. The prevalence and location of metastases
from ocular melanoma: imaging study in 110 patients. AJ. Am. J. Roentgenol. 157
(6), 1279–1281.
Mazzini, C., Pinzani, P., Salvianti, F., Scatena, C., Paglierani, M., Ucci, F., Pazzagli, M., Massi,
D., 2014. Circulating tumor cells detection and counting in uveal melanomas by a ﬁl-
tration-based method. Cancers 6 (1), 323–332.
Mehes, G., Witt, A., Kubista, E., Ambros, P.F., 2001. Circulating breast cancer cells are fre-
quently apoptotic. Am. J. Pathol. 159 (1), 17–20.
Menyaev, Y.A., Nedosekin, D.A., Sarimollaoglu, M., Juratli, M.A., Galanzha, E.I., Tuchin, V.V.,
Zharov, V.P., 2013. Optical clearing in photoacoustic ﬂow cytometry. Biomed. Opt. Ex-
press 4 (12), 3030–3041.
Rao, C., Bui, T., Connelly, M., Doyle, G., Karydis, I., Middleton, M.R., Clack, G., Malone, M.,
Coumans, F.A., Terstappen, L.W., 2011. Circulating melanoma cells and survival in
metastatic melanoma. Int. J. Oncol. 38 (3), 755–760.
Rietschel, P., Panageas, K.S., Hanlon, C., Patel, A., Abramson, D.H., Chapman, P.B., 2005.
Variates of survival in metastatic uveal melanoma. J. Clin. Oncol. 23 (31), 8076–8080.
Sarimollaoglu, M., Nedosekin, D.A., Menyaev, Y.A., Juratli, M.A., Zharov, V.P., 2014. Nonlin-
ear photoacoustic signal ampliﬁcation from single targets in absorption background.
Photoacoustics 2 (1), 1–11.
Singh, A.D., Shields, C.L., Shields, J.A., 2001. Prognostic factors in uveal melanoma.Melano-
ma Res. 11 (3), 255–263.
Singh, A.D., Turell, M.E., Topham, A.K., 2011. Uveal melanoma: trends in incidence, treat-
ment, and survival. Ophthalmology 118 (9), 1881–1885.
Suesskind, D., Ulmer, A., Schiebel, U., Fierlbeck, G., Spitzer, B., Spitzer, M.S., Bartz-Schmidt,
K.U., Grisanti, S., 2011. Circulating melanoma cells in peripheral blood of patients
with uveal melanoma before and after different therapies and association with prog-
nostic parameters: a pilot study. Acta Ophthalmol. (Copenh) 89 (1), 17–24.
Tura, A., Luke, J., Merz, H., Reinsberg, M., Luke, M., Jager, M.J., Grisanti, S., 2014. Identiﬁca-
tion of circulating melanoma cells in uveal melanoma patients by dual-marker
immunoenrichment. Invest. Ophthalmol. Vis. Sci. 55 (7), 4395–4404.
Weissenstein, U., Schumann, A., Reif, M., Link, S., Toffol-Schmidt, U.D., Heusser, P., 2012.
Detection of circulating tumor cells in blood of metastatic breast cancer patients
using a combination of cytokeratin and EpCAM antibodies. BMC Cancer 12, 206.
Yoshida, M., Selvan, S., McCue, P.A., DeAngelis, T., Baserga, R., Fujii, A., Rui, H., Mastrangelo,
M.J., Sato, T., 2014. Expression of insulin-like growth factor-1 receptor in metastatic
uveal melanoma and implications for potential autocrine and paracrine tumor cell
growth. Pigment Cell Melanoma Res. 27 (2), 297–308.
